Increased serum soluble programmed death ligand 1(sPD-L1) is associated with the presence of interstitial lung disease in rheumatoid arthritis: A monocentric cross-sectional study - 28/07/20
, Jing Xue a, ⁎ Abstract |
Objective |
This paper is to examine the relationship between serum soluble programmed death ligand 1(sPD-L1) levels and the development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).
Method |
Serum sPD-L1 were measured by enzyme-linked immunosorbent assay. sPD-L1 levels in RA with ILD, RA without ILD and healthy controls were compared. Associations between ILD and various markers including sPD-L1 and confounding factors were investigated by logistic regression analysis. Diagnostic values of sPD-L1 for the presence of ILD were investigated using receiver operating characteristics curve analysis.
Results |
Serum sPD-L1 levels were higher in RA patients with ILD than RA patients without ILD and healthy controls (23.7 ± 9.8 vs. 18.0 ± 7.7 pg/mL, P = 0.01 and 23.7 ± 9.8 vs. 2.9 ± 1.5 pg/mL, P < 0.0001). sPD-L1 levels were positively correlated with RF titer (r = 0.245, P = 0.03), CRP (r = 0.265,P = 0.01), HRCT score (r = 0.265, P = 0.04) and Ferritin (r = 0.442, P = 0.01), but negatively associated with FVC% (r = −0.359, P = 0.01) and DLCO% (r = −0.399, P = 0.008). sPD-L1 and anti-CCP antibody status were independently associated with the presence of ILD during multivariate logistic regression analysis. Sensitivity and specificity of sPD-L1 levels for the detection of ILD in RA patients were 51.7% and 79.3%, respectively (area under the curve = 0.661).
Conclusion |
Serum sPD-L1 levels were increased in RA patients with ILD. Increased sPD-L1 levels were associated with the presence of ILD.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Serum sPD-L1 levels were increased in RA-ILD. |
• | SPD-L1 levels were negatively associated with pulmonary function in RA-ILD. |
• | SPD-L1 was independently associated with the presence of RA-ILD. |
Keywords : Rheumatoid arthritis, sPD-L1, Interstitial lung disease
Plan
Vol 166
Article 105948- mai 2020 Retour au numéro
Article précédent
- Goals of COPD treatment: Focus on symptoms and exacerbations
- Claus F. Vogelmeier, Miguel Román-Rodríguez, Dave Singh, MeiLan K. Han, Roberto Rodríguez-Roisin, Gary T. Ferguson
- Impact of Aspergillus precipitating antibody test results on clinical outcomes of patients with Mycobacterium avium complex lung disease
- Tatsuya Shirai, Koji Furuuchi, Keiji Fujiwara, Keitaro Nakamoto, Yoshiaki Tanaka, Haruyuki Ishii, Takashi Yoshiyama, Kozo Yoshimori, Hajime Takizawa, Yuka Sasaki, Atsuyuki Kurashima, Ken Ohta, Kozo Morimoto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?